Unit Price:
৳ 30.00
(3 x 10: ৳ 900.00)
Strip Price:
৳ 300.00
Indications
Osmifen is an estrogen agonist/antagonist indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Pharmacology
Ospemifene is a next-generation SERM (selective estrogen receptor modulator) that selectively binds to estrogen receptors and either stimulates or blocks estrogen’s activity in different tissue types. It has an agonistic effect on the endometrium.
Dosage & Administration
Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause: 60 mg tablet with food once daily.
Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause: 60 mg tablet with food once daily.
Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy, due to menopause: 60 mg tablet with food once daily.
Interaction
Osmifen is primarily metabolized by CYP3A4 and CYP2C9. CYP2C19 and other pathways contribute to the metabolism of Osmifen.
Estrogens and Estrogen Agonist/Antagonist: Do not use Osmifen concomitantly with estrogens and estrogen agonists/antagonists. The safety of concomitant use of Osmifen with estrogens and estrogen agonists/antagonists has not been studied.
Fluconazole: Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with Osmifen. Fluconazole increases the systemic exposure of Osmifen by 2.7-fold. Administration of fluconazole with Osmifen may increase the risk of Osmifen-related adverse reactions.
Rifampin: Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of Osmifen by 58%. Therefore, co-administration of Osmifen with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of Osmifen, which may decrease the clinical effect
Ketoconazole: Ketoconazole, a strong CYP3A4 inhibitor, increases the systemic exposure of Osmifen by 1.4-fold. Administration of ketoconazole chronically with Osmifen may increase the risk of Osmifen related adverse reactions.
Warfarin: Repeated administration of Osmifen had no effect on the pharmacokinetics of a single 10 mg dose of warfarin. No study was conducted with multiple doses of warfarin. The effect of Osmifen on clotting time such as the International Normalized Ratio (INR) or prothrombin time (PT) was not studied.
Highly Protein-Bound Drugs: Osmifen is more than 99% bound to serum proteins and might affect the protein binding of other drugs. Use of Osmifen with other drug products that are highly protein-bound may lead to increased exposure of either that drug or Osmifen.
Multiple Enzyme Inhibition: Co-administration of Osmifenwith a drug known to inhibit CYP3A4 and CYP2C9 isoenzymes may increase the risk of Osmifen -related adverse reactions.
Estrogens and Estrogen Agonist/Antagonist: Do not use Osmifen concomitantly with estrogens and estrogen agonists/antagonists. The safety of concomitant use of Osmifen with estrogens and estrogen agonists/antagonists has not been studied.
Fluconazole: Fluconazole, a moderate CYP3A / strong CYP2C9 / moderate CYP2C19 inhibitor, should not be used with Osmifen. Fluconazole increases the systemic exposure of Osmifen by 2.7-fold. Administration of fluconazole with Osmifen may increase the risk of Osmifen-related adverse reactions.
Rifampin: Rifampin, a strong CYP3A4 / moderate CYP2C9 / moderate CYP2C19 inducer, decreases the systemic exposure of Osmifen by 58%. Therefore, co-administration of Osmifen with drugs such as rifampin which induce CYP3A4, CYP2C9 and/or CYP2C19 activity would be expected to decrease the systemic exposure of Osmifen, which may decrease the clinical effect
Ketoconazole: Ketoconazole, a strong CYP3A4 inhibitor, increases the systemic exposure of Osmifen by 1.4-fold. Administration of ketoconazole chronically with Osmifen may increase the risk of Osmifen related adverse reactions.
Warfarin: Repeated administration of Osmifen had no effect on the pharmacokinetics of a single 10 mg dose of warfarin. No study was conducted with multiple doses of warfarin. The effect of Osmifen on clotting time such as the International Normalized Ratio (INR) or prothrombin time (PT) was not studied.
Highly Protein-Bound Drugs: Osmifen is more than 99% bound to serum proteins and might affect the protein binding of other drugs. Use of Osmifen with other drug products that are highly protein-bound may lead to increased exposure of either that drug or Osmifen.
Multiple Enzyme Inhibition: Co-administration of Osmifenwith a drug known to inhibit CYP3A4 and CYP2C9 isoenzymes may increase the risk of Osmifen -related adverse reactions.
Contraindications
- Undiagnosed abnormal genital bleeding. Known or suspected estrogen-dependent neoplasia.
- Active DVT, pulmonary embolism (PE), or a history of these conditions.
- Active arterial thromboembolic disease [for example, stroke and myocardial infarction, or a history of these conditions.
- Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) or any ingredients.
Side Effects
- Cardiovascular Disorders
- Malignant Neoplasms
- Vascular Disorders: Hot flush
- Reproductive System and Breast Disorders: Vaginal discharge
- Musculoskeletal and Connective Tissue Disorders: Muscle spasms
- Skin and Subcutaneous Tissue Disorders: Hyperhidrosis
Pregnancy & Lactation
Use in Pregnancy: Ospemifene is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus.Based on animal data, it is likely to increase the risk of adverse outcomes during pregnancy and labor. Adverse findings at maternally toxic doses included embryo fetal lethality in rats and rabbits, and neonatal mortality and difficult labor in rats. The reproductive effects observed are consistent with and are considered to be related to estrogen receptor activity of Ospemifene.
Use in Lactation: It is not known whether Ospemifene is excreted in human breast milk. There are no data on the effects of Ospemifene on the breastfed child or the effects on milk production. Do not breastfeed while taking Ospemifene. Ospemifene was excreted in rat milk.
Use in Lactation: It is not known whether Ospemifene is excreted in human breast milk. There are no data on the effects of Ospemifene on the breastfed child or the effects on milk production. Do not breastfeed while taking Ospemifene. Ospemifene was excreted in rat milk.
Precautions & Warnings
Cardiovascular Disorders: Risk factors for cardiovascular disorders, arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
Stroke: In the clinical trials for Osmifen (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively in Osmifen 60 mg treatment group and 3.15 and 0 per thousand women years in placebo.
Coronary Heart Disease: In the clinical trials, two cases of myocardial infarction (MI) occurred in women receiving 60 mg of Osmifen. In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo.
Venous Thromboembolism: In the Osmifen clinical trials, two cases of DVT occurred in women receiving Osmifen 60 mg. Should a VTE occur or be suspected, Osmifen should be discontinued immediately. If feasible, Osmifen should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
Endometrial Cancer: Osmifen is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, Osmifen has agonistic effects. In the Osmifen clinical trials (60 mg treatment group), no cases of endometrial cancer were seen with exposure up to 52 weeks. There was a single case of simple hyperplasia without atypia. Endometrial thickening equal to 5 mm or greater was seen in the Osmifen up to 52 weeks treatment groups at a rate of 101.4 per thousand women vs. 20.9 per thousand women for placebo. The incidence of any type of proliferative (weakly plus active plus disordered) endometrium was 26.3 per thousand women in the Osmifen up to 52 weeks treatment groups vs. 0 per thousand women for placebo. Uterine polyps occurred at an incidence of 19.6 per thousand women in the Osmifen up to 52 weeks treatment groups vs. 8.3 per thousand women for placebo. Clinical surveillance of all women using Osmifen is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Breast Cancer: Osmifen 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer.
Severe Hepatic Impairment: Osmifen should not be used in women with severe hepatic impairment
Hypersensitivity Reactions: Inform postmenopausal women who have had hypersensitivity reactions to Osmifen such as angioedema, urticaria, rash, and pruritus, that they should not take.
Vaginal Bleeding: Inform postmenopausal women of the importance of reporting unusual vaginal bleeding to their healthcare providers as soon as possible.
Hot Flashes or Flushes: Osmifen may initiate or increase the occurrence of hot flashes in some women.
Carcinogenesis: In a 2-year carcinogenicity study in female mice, Osmifen was orally administered at 100, 400, or 1500 mg/kg/day. No evaluation for carcinogenicity was conducted in male mice. There was significant increase in adrenal subcapsular cell adenomas at 4 and 5 times the human exposure based on AUC, and adrenal cortical tumors at 5 times the human exposure. In the ovary, an increase in sex cord/stromal tumors, tubulostromal tumors, granulosa cell tumors, and luteomas were also seen. These findings occurred at doses 2 to 5 times the human exposure based on AUC and are probably related to estrogenic/antiestrogenic effect of Osmifen in mice.
Mutagenesis: Osmifen was not genotoxic in vitro in the Ames test in strains of Salmonella typhimurium or at the thymidine kinase (tk) locus of mouse lymphoma L5178Y cells in the absence and in the presence of a metabolic activator system. In in vivo testing, Osmifen was not genotoxic in a standard mouse bone marrow micronucleus test or in a determination of DNA adducts in the liver of rats.
Impairment of Fertility: The effect of Osmifen on fertility was not directly evaluated. In female rats and monkeys, decreases in ovarian and uterine weights, decreased corpora lutea number, increased ovarian cysts, uterine atrophy, and disrupted cycles were observed when given repeated daily oral doses. In male rats, atrophy of the prostate and seminal vesicles was noted. The effects on reproductive organs observed in animals are consistent with the estrogen receptor activity of Osmifen and potential for impairment of fertility.
Stroke: In the clinical trials for Osmifen (duration of treatment up to 15 months), the incidence rates of thromboembolic and hemorrhagic stroke were 1.13 and 3.39 per thousand women years, respectively in Osmifen 60 mg treatment group and 3.15 and 0 per thousand women years in placebo.
Coronary Heart Disease: In the clinical trials, two cases of myocardial infarction (MI) occurred in women receiving 60 mg of Osmifen. In the WHI estrogen-alone substudy, no overall effect on coronary heart disease (CHD) events (defined as nonfatal MI, silent MI, or CHD death) was reported in women receiving estrogen-alone compared to placebo.
Venous Thromboembolism: In the Osmifen clinical trials, two cases of DVT occurred in women receiving Osmifen 60 mg. Should a VTE occur or be suspected, Osmifen should be discontinued immediately. If feasible, Osmifen should be discontinued at least 4 to 6 weeks before surgery of the type associated with an increased risk of thromboembolism, or during periods of prolonged immobilization.
Endometrial Cancer: Osmifen is an estrogen agonist/antagonist with tissue selective effects. In the endometrium, Osmifen has agonistic effects. In the Osmifen clinical trials (60 mg treatment group), no cases of endometrial cancer were seen with exposure up to 52 weeks. There was a single case of simple hyperplasia without atypia. Endometrial thickening equal to 5 mm or greater was seen in the Osmifen up to 52 weeks treatment groups at a rate of 101.4 per thousand women vs. 20.9 per thousand women for placebo. The incidence of any type of proliferative (weakly plus active plus disordered) endometrium was 26.3 per thousand women in the Osmifen up to 52 weeks treatment groups vs. 0 per thousand women for placebo. Uterine polyps occurred at an incidence of 19.6 per thousand women in the Osmifen up to 52 weeks treatment groups vs. 8.3 per thousand women for placebo. Clinical surveillance of all women using Osmifen is important. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Breast Cancer: Osmifen 60 mg has not been adequately studied in women with breast cancer; therefore, it should not be used in women with known or suspected breast cancer.
Severe Hepatic Impairment: Osmifen should not be used in women with severe hepatic impairment
Hypersensitivity Reactions: Inform postmenopausal women who have had hypersensitivity reactions to Osmifen such as angioedema, urticaria, rash, and pruritus, that they should not take.
Vaginal Bleeding: Inform postmenopausal women of the importance of reporting unusual vaginal bleeding to their healthcare providers as soon as possible.
Hot Flashes or Flushes: Osmifen may initiate or increase the occurrence of hot flashes in some women.
Carcinogenesis: In a 2-year carcinogenicity study in female mice, Osmifen was orally administered at 100, 400, or 1500 mg/kg/day. No evaluation for carcinogenicity was conducted in male mice. There was significant increase in adrenal subcapsular cell adenomas at 4 and 5 times the human exposure based on AUC, and adrenal cortical tumors at 5 times the human exposure. In the ovary, an increase in sex cord/stromal tumors, tubulostromal tumors, granulosa cell tumors, and luteomas were also seen. These findings occurred at doses 2 to 5 times the human exposure based on AUC and are probably related to estrogenic/antiestrogenic effect of Osmifen in mice.
Mutagenesis: Osmifen was not genotoxic in vitro in the Ames test in strains of Salmonella typhimurium or at the thymidine kinase (tk) locus of mouse lymphoma L5178Y cells in the absence and in the presence of a metabolic activator system. In in vivo testing, Osmifen was not genotoxic in a standard mouse bone marrow micronucleus test or in a determination of DNA adducts in the liver of rats.
Impairment of Fertility: The effect of Osmifen on fertility was not directly evaluated. In female rats and monkeys, decreases in ovarian and uterine weights, decreased corpora lutea number, increased ovarian cysts, uterine atrophy, and disrupted cycles were observed when given repeated daily oral doses. In male rats, atrophy of the prostate and seminal vesicles was noted. The effects on reproductive organs observed in animals are consistent with the estrogen receptor activity of Osmifen and potential for impairment of fertility.
Use in Special Populations
Pediatric Use: Osmifen is not indicated in children. Clinical studies have not been conducted in the pediatric population.
Geriatric Use: Of the 2209 Osmifen-treated women enrolled in the ten phase 2/3 trials of Osmifen, >19 percent were 65 years of age or older. No clinically meaningful differences in safety or effectiveness were observed between these women and younger women less than 65 years of age.
Renal Impairment: The pharmacokinetics of Osmifen in women with severe renal impairment (CrCL <30 mL/min) was similar to those in women with normal renal function. No dose adjustment of Osmifen is required in women with renal impairment.
Hepatic Impairment: The pharmacokinetics of Osmifen has not been studied in women with severe hepatic impairment (Child-Pugh Class C); therefore, do not use Osmifen in women with severe hepatic impairment
Geriatric Use: Of the 2209 Osmifen-treated women enrolled in the ten phase 2/3 trials of Osmifen, >19 percent were 65 years of age or older. No clinically meaningful differences in safety or effectiveness were observed between these women and younger women less than 65 years of age.
Renal Impairment: The pharmacokinetics of Osmifen in women with severe renal impairment (CrCL <30 mL/min) was similar to those in women with normal renal function. No dose adjustment of Osmifen is required in women with renal impairment.
Hepatic Impairment: The pharmacokinetics of Osmifen has not been studied in women with severe hepatic impairment (Child-Pugh Class C); therefore, do not use Osmifen in women with severe hepatic impairment
Therapeutic Class
Drugs used in Vaginal and Vulval condition
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
Pack Image: Osmifen 60 mg Tablet